Collegium Pharmaceutical
Manufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
100 Technology Center Dr, Stoughton, Mas...Phone Number
(781) 713-3699Website
www.collegiumpharma.comRevenue
$796.3 MillionStock Symbol
COLLIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Explore more
Collegium Pharmaceutical Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Collegium Pharmaceutical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Collegium Pharmaceutical recently announced quarterly report
Click to see if Collegium Pharmaceutical had a recent Job posting/layoffs
Check if Collegium Pharmaceutical has recently received funding, and reach out quickly before it becomes old news!
Collegium Pharmaceutical, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Collegium Pharmaceutical
Funding: Get notified immidiatlly once Collegium Pharmaceutical has new funding data
Check out if Collegium Pharmaceutical is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Collegium Pharmaceutical launches new products
Recommended Actions
Find VP level buyers at Collegium Pharmaceutical
Find more new buyers
Compare Similar Companies to Collegium Pharmaceutical
Compare insights from companies similar to Collegium Pharmaceutical, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Collegium Pharmaceutical is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Collegium Pharmaceutical is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Collegium Pharmaceutical.
Collegium Pharmaceutical financials insights
Gather financial insights about Collegium Pharmaceutical, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Debt
$1M
2012
Series B
$22.5M
2013
Private Equity
$4M
2015
Other Financing Round
$50M
Stock Offering
$69.6M
2016
Stock Offering
$55M
Stock Offering
$80M
2020
Stock Offering
$125M
2022
Debt
$650M
Collegium Pharmaceutical Tech Stack
A closer look at the technologies used by Collegium Pharmaceutical
See more technologies
Most Recent Scoops
Open Position
Person-Based
Product Development, Research & Development, Marketing Strategy
Partnership
Collegium Pharmaceutical has entered into an authorized generic supply arrangement with Hikma, under which Hikma launched authorized generics for both Nucynta ER and Nucynta IR in late February and early March, respectively, with Collegium Pharmaceutical supplying the product and receiving a high profit share on Hikma's sales.
Partnership
Earnings
Collegium Pharmaceutical has reported that Jornay PM gross-to-net improved from approximately 71% in fiscal year 2024 to approximately 64% in fiscal year 2025, with full-year 2026 gross-to-net expected to be in the mid-60% range and Q1 2026 gross-to-net coming in just under 68%, compared to just under 70% in Q1 2025.
Earnings
Earnings
Earnings, Finance
Collegium Pharmaceutical News & Media
Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
STOUGHTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report second quarter 2026 financial results before the market opens on Thursday August 6, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
New headquarters reflects Collegium's long-term vision and commitment to Massachusetts New headquarters reflects Collegium's long-term vision and commitment to MassachusettsCollegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it awarded inducement grants on June 1, 2026 under the Company's 2026 Inducement Plan (the 2026 Inducement Plan).Interested in Collegium Pharmaceutical Inc (COLL) Stock? Look at ADHD Portfolio
Collegium Pharmaceutical Inc (NASDAQ:COLL) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. Analysts expect the stock to gain 57% over the next 12 months. On May 7, Collegium Pharmaceutical Inc (NASDAQ:COLL) reported Q1 2026 results that both increased from the prior year and exceeded the […]
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Collegium Pharmaceutical
Sign Up For FreeTo access detailed company insights
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioi... Read More
